Polycystic Ovary Syndrome-Emam

  • View
    218

  • Download
    0

Embed Size (px)

Citation preview

  • 8/3/2019 Polycystic Ovary Syndrome-Emam

    1/31

    BY

    Mohammad EmamProf. OB& GYN

    Mansoura Faculty of Medicine

    Mansoura integrated fertility center (MIFC)

    EGYPT

    Polycystic Ovary Syndrome In

    The Era Of Metabolic Syndrome

  • 8/3/2019 Polycystic Ovary Syndrome-Emam

    2/31

    Syndrome X =IRMetabolic Syndrome ( MS) =

    Is a cluster of metabolicdisorders, with a

    subnormal biologicalresponse to insulinoccurring mainly invisceral obesity.

    The more components of the syndrome ,

    the greater the risks .

  • 8/3/2019 Polycystic Ovary Syndrome-Emam

    3/31

    ooGlucoseGlucoseV. ObesityV. Obesity

    qq HDLHDL--CC

    oo BPBP

    oo TGTG

    Glucose u 6.1mmol/L

    Waist Circumference

    bu 102cm

    cu 88cm

    HDL-C

    b1.0 mmols/L

    c 1.3 mmols/L

    BP u130/u85 mmHg

    Triglycerides u 1.7mmol/L

    Diagnostic Criteria forDiagnostic Criteria forMetabolic SyndromeMetabolic Syndrome

    Diagnosis is made when 3 or more

    of these risk criteria are met

  • 8/3/2019 Polycystic Ovary Syndrome-Emam

    4/31

    Two of the following three features are present,

    after exclusion of other etiologies :

    (i) Oligomenorrhoea and or Anovulation

    (ii) Hyperandrogenism and/or hyperandrogenemia.

    (iii) Polycystic ovaries (sonar).

    Definition PCOSDefinition PCOS

    ( Rotterdam( Rotterdam 20032003))

  • 8/3/2019 Polycystic Ovary Syndrome-Emam

    5/31

    Phenotypes (Rotterdam)Phenotypes (Rotterdam)

    PCOS WITH PCO .PCO + HYPERANDROGENISM + ANOVULATION.

    PCO + Hyperandrogenism.

    PCO + Anovulation.

    PCOS WITHOUT PCO .Hyperandrogenism + Anovulation.

    PCO WITHOUT PCOS.( Isolated PCO = Asymptomatic PCO ).

  • 8/3/2019 Polycystic Ovary Syndrome-Emam

    6/31

    What is The significance of PCO in PCOS??What is The significance of PCO in PCOS??

    The presence of PCO

    usually correlateswith the presence of

    insulin resistance(Richard J 2002).

  • 8/3/2019 Polycystic Ovary Syndrome-Emam

    7/31

    Prevalence Of MS In PCOS

    MS is present in 2/3 of thePCOS (2-fold higher than

    women in the generalpopulation).

  • 8/3/2019 Polycystic Ovary Syndrome-Emam

    8/31

    Pitfalls Rotterdam Definition

    1. doubts still exist regarding borderlinegroups of patients ,such as hirsute

    ovulatory Normoandrogenic women

    with PCO???.

    2. Neglect role of IR

  • 8/3/2019 Polycystic Ovary Syndrome-Emam

    9/31

    PCOS + IR (70 % ).

    PCOS without IR (Legro etal 2004).

    Phenotypes Of PCOSAccording to IR

  • 8/3/2019 Polycystic Ovary Syndrome-Emam

    10/31

    1) IR Phenotype of PCOS

    Abdominal obesity ( Minority may be lean)

    Acanthosis Nigericans.

    Hirsutism. Resistance to CC,

  • 8/3/2019 Polycystic Ovary Syndrome-Emam

    11/31

    2) PCOS Without IR

    Lean.

    Euinsulinemic/Euglycemic

    Enhanced OvarianSensitivity to insulin(although no hyperinsulinemia).

  • 8/3/2019 Polycystic Ovary Syndrome-Emam

    12/31

    RATIONALE

    MSIs associated with medical and psychosocial co-

    morbidities that are both immediate and long-term

    ( PCOS Is one of these co-morbidities ).

    PCOS:

    PCOS is now recognized as an importantmetabolic and reproductive disorder .

    So, Overlap and vicious circle can be present

    between PCOS and MS.

  • 8/3/2019 Polycystic Ovary Syndrome-Emam

    13/31

    Co-morbidities With IR

  • 8/3/2019 Polycystic Ovary Syndrome-Emam

    14/31

    Objective

    To illustrate the link between two current

    ,intimate and hidden epidemics , MS and

    PCOS .

    To pinpoint the role of gynecologists

    regarding the management ofPCOS in the

    era of MS.

  • 8/3/2019 Polycystic Ovary Syndrome-Emam

    15/31

    Link between MS & PCOS

    PCOSPCOSMSMS

    IRIR

  • 8/3/2019 Polycystic Ovary Syndrome-Emam

    16/31

    The Central Player

    ( Insulin Resistance & Vicious circle )

    Genetics

    AgingPregnancy Drugs Lifestyle

    obesity

    HyperinsulinemiaIncreased lipid storage

    Altered lipoprotein &

    cholesterol metabolismAltered steroid

    hormone metabolism

    PCOS

    Insulin

    Resistance

  • 8/3/2019 Polycystic Ovary Syndrome-Emam

    17/31

    The high ovarianresponse to insulin.

    Opposed by the wholebody resistance.

    IR : The central paradox

  • 8/3/2019 Polycystic Ovary Syndrome-Emam

    18/31

    Genetic Of (MS) & PCOS

    There is evidence for linkage

    of the hyperandrogenemiaphenotype with an allele of amarker locus on chromosome

    19, in the region ofthe geneencoding the insulin receptor.

  • 8/3/2019 Polycystic Ovary Syndrome-Emam

    19/31

    E E

    F F

    Insulina

    Types of insulin resistanceTypes of insulin resistance

    Type B

    Type A

    Type C

    Autoantibodies

    to insulin receptorsGenetic defectof insulin receptor

    (Kahn syndrome)

    Defect of tyrozine

    kinase

    tyrozine kinase

  • 8/3/2019 Polycystic Ovary Syndrome-Emam

    20/31

    How IR Can Be Confirmed ??

    Fasting glucose / insulin < 4.5

    Fasting insulin > 24 uU / ml

    One hour insulin post OGTT-75 gm > 150

    uU/ml

  • 8/3/2019 Polycystic Ovary Syndrome-Emam

    21/31

    Targets for ttt

    IR None IR

    Causative ttt

    ( Insulin sensitizers)

    Symptomatic ttt + Insulin

    sensitizers ( prevent

    Hyperandrogenism IRVicious circle ) :

    Acne.

    Hirsutism.

    INFERTILITYT

    PCOS

  • 8/3/2019 Polycystic Ovary Syndrome-Emam

    22/31

    Causative

    ttt

    Life- style modifications:

    Diet modificationWeight loss

    Exercise

    Psychosocial support.

    Cessation smoking.

    Improve IR ( Metformin)

  • 8/3/2019 Polycystic Ovary Syndrome-Emam

    23/31

    Proposed Approach for ttt of Anovulation In PCOS

    Baseline evaluation ( Semenogram , HSG , Midluteal p)

    Life style modification ( Exercise , Wt loss , Prohibit smoking

    Metformin 500mg / day x first week , then 500 bd on week 2 ,then 500 tds from week 3 till 6-12 month . ( Ensure liver and

    renal functions prior ttt )

    Not pregnant addCC for 6 cycles

    Pregnant: continueMetformin first

    trimesterNot pregnant , consider GN ,

    OVDrilling , IUI , I

    VFOR ICSI

  • 8/3/2019 Polycystic Ovary Syndrome-Emam

    24/31

    The advantages of Metformin over drilling

    continue beyond conception:

    It reduces the miscarriage rate.

    Decreases the development of

    gestational diabetes.

  • 8/3/2019 Polycystic Ovary Syndrome-Emam

    25/31

    Indications OfD

    rilling

    Regressed behind.Failure of :

    Change of life style.

    Insulin sensitizing agents.CC +/- HMG.

  • 8/3/2019 Polycystic Ovary Syndrome-Emam

    26/31

    Role Of Metformin In None IR( PCOS)

    Prevents starting vicious circle of hyperandrogenemia -IR.

    Improve spontaneous and CC-induced ovulation.

    Improve follicular maturation in IVF cycles.

    The continuation in the first trimester appearsto reduce the risk of abortion

    ( Metformin = FDA group B ).

  • 8/3/2019 Polycystic Ovary Syndrome-Emam

    27/31

    Conclusions

    We are facing two current

    intimate epidemics ( MS &PCOS ) which affect a large scale

    of population and also affecttheir reproductive future.

  • 8/3/2019 Polycystic Ovary Syndrome-Emam

    28/31

    Gynecologists should categorize any case of PCOS,depending on :

    1. Rotterdam criteria.

    2.IR or not

    Conclusions

  • 8/3/2019 Polycystic Ovary Syndrome-Emam

    29/31

    conclusionsInsulin sensitizers are the milestone in ttt of PCOS :

    whether as a causative therapy in( IR) sub phenotype.

    OR AS

    A prohibitor of the starting

    Hyperandrogenemia- IR vicious circle

    in (none IR) sub phenotype

    Conclusions

  • 8/3/2019 Polycystic Ovary Syndrome-Emam

    30/31

    We are inAt The Endneed for an applicable

    integrated classification ofPCOS to satisfy different

    specialists at the same

    time!!!!

  • 8/3/2019 Polycystic Ovary Syndrome-Emam

    31/31

    Telfax 0020502319922 & 0020502312299

    Email. [email protected]